Hit enter to search or ESC to close
Company
Science
Pipeline
Newsroom
Investors
Careers
Contact
Overview
News Releases
Events
Stock Information
Quote
Interactive Chart
Corporate Governance
Documents & Charters
Board Committees
Financial Information
Snapshot
SEC Filings
Analyst Coverage
Key Ratios
Investor Resources
Contact IR
FAQs
Investor Alerts
RSS
Investors Menu
Overview
News Releases
Events
Stock Information
Quote
Interactive Chart
Corporate Governance
Documents & Charters
Board Committees
Financial Information
Snapshot
SEC Filings
Analyst Coverage
Key Ratios
Investor Resources
Contact IR
FAQs
Investor Alerts
RSS
News Releases
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Investor Alerts
Year
All Years
2023
2022
2021
2020
2019
2018
2017
2016
Keywords
Go
Advanced Search
Search
Search Headlines Only
From
To
May 30, 2023
IDEAYA Biosciences to Participate in Upcoming June 2023 Investor Relations Events
May 26, 2023
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 22, 2023
IDEAYA Announces IND Clearance Enabling Phase 1/2 Clinical Trial for Combination of IDE397 and AMG 193 in MTAP-Deletion Solid Tumors
May 16, 2023
IDEAYA Expands Clinical Trial Collaboration and Supply Agreements with Pfizer to Support Registrational Trial Evaluating Darovasertib and Crizotinib Combination in First-Line Metastatic Uveal Melanoma
May 9, 2023
IDEAYA Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update
May 1, 2023
IDEAYA Biosciences to Participate in Upcoming May 2023 Investor Relations Event
Apr 28, 2023
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Apr 27, 2023
IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Apr 24, 2023
IDEAYA Announces Pricing of Public Offering
Apr 24, 2023
IDEAYA Announces Proposed Public Offering of Common Stock
Apr 23, 2023
IDEAYA Announces Positive Interim Phase 2 Data for Darovasertib and Crizotinib Combination and Successful FDA Type C Meeting on Registrational Trial Design for Accelerated Approval in First-Line Metastatic Uveal Melanoma
Apr 19, 2023
IDEAYA Announces First Patient Dosed in Phase 1 Clinical Trial for IDE161 as Potential First-in-Class PARG Inhibitor Targeting HRD Solid Tumors
Apr 3, 2023
IDEAYA Biosciences to Participate in Upcoming April 2023 Investor Relations Event
Mar 31, 2023
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Mar 14, 2023
IDEAYA Announces Presentations at AACR Annual Meeting 2023 for Potential First-in-Class Synthetic Lethality Programs IDE397 (MAT2A), IDE161 (PARG) and Werner Helicase
Mar 7, 2023
IDEAYA Biosciences, Inc. Reports 2022 Financial Results and Provides Business Update
Mar 1, 2023
IDEAYA Biosciences to Participate in Investor Conferences in March 2023
Feb 16, 2023
IDEAYA Biosciences to Participate in Citi's 2023 Virtual Oncology Leadership Summit
Feb 1, 2023
IDEAYA Biosciences to Participate in the 2023 Guggenheim Oncology Conference
Jan 23, 2023
IDEAYA Announces Darovasertib Phase 2 Initiation in Neoadjuvant and Adjuvant Uveal Melanoma and Guidance for Clinical Data Update in Metastatic Uveal Melanoma
Jan 9, 2023
IDEAYA Announces IND Clearance by U.S. FDA enabling Phase 1 Initiation for First-in-Class PARG Development Candidate IDE161
Jan 3, 2023
IDEAYA Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023
Dec 19, 2022
IDEAYA Biosciences Appoints Dr. Karlene Cimprich, Ph.D. and Dr. Kornelia Polyak, M.D., Ph.D. to Scientific Advisory Board
Dec 12, 2022
IDEAYA Biosciences Announces Submission of IND Application to the U.S. FDA for PARG Development Candidate IDE161
Dec 5, 2022
IDEAYA Biosciences Receives Fast Track Designation for Darovasertib Combination Therapy with Crizotinib for the Treatment of Metastatic Uveal Melanoma
Nov 29, 2022
IDEAYA Biosciences Announces Agenda Topics and Key Opinion Leader Presenters for Investor R&D Day Webcast on Monday, December 12, 2022
Nov 28, 2022
IDEAYA Biosciences Appoints Darrin M. Beaupre, M.D., Ph.D., as Chief Medical Officer to Lead Clinical Development of Expanding Clinical Pipeline
Nov 8, 2022
IDEAYA Biosciences, Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update
Nov 1, 2022
IDEAYA Biosciences Announces Plans for Investor R&D Day and Participation in Upcoming Investor Conferences
Oct 18, 2022
IDEAYA Announces Phase 2 MAT2A Inhibitor, IDE397, Achieves First-Patient-In for Multiple Combination Cohorts in MTAP-Deletion Tumors
Sep 19, 2022
IDEAYA Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
Sep 14, 2022
IDEAYA Announces Pricing of Public Offering of Common Stock
Sep 14, 2022
IDEAYA Announces Proposed Public Offering of Common Stock
Sep 11, 2022
IDEAYA Reports Positive Interim Phase 2 Clinical Results for Darovasertib and Crizotinib Synthetic Lethal Combination in Metastatic Uveal Melanoma
Sep 6, 2022
IDEAYA Announces First-Patient-In for Phase I Clinical Trial to Evaluate Darovasertib Monotherapy in (Neo)Adjuvant Uveal Melanoma
Aug 30, 2022
IDEAYA Biosciences to Participate in Investor Conferences in September 2022
Aug 29, 2022
IDEAYA Announces Achievement of First Milestone in Ongoing Collaboration with GSK for Potential First-in-Class Pol Theta Helicase Inhibitor Development Candidate
Aug 15, 2022
IDEAYA Biosciences, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update
Jul 27, 2022
IDEAYA Announces IDE397 Clinical Program Update and ctDNA Molecular Responses Demonstrating Tumor Pharmacodynamic Modulation
Jul 27, 2022
IDEAYA Announces Clinical Trial Collaboration with Amgen to Evaluate MAT2A-PRMT5 Synthetic Lethality Combination in MTAP Deleted Tumors
Jun 28, 2022
IDEAYA Announces Development Candidate Nomination of a Potential First-in-Class Pol Theta Helicase Inhibitor in Collaboration with GSK
Jun 8, 2022
IDEAYA Biosciences to Present at the 2022 Jefferies Global Healthcare Conference
May 10, 2022
IDEAYA Biosciences, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update
May 3, 2022
IDEAYA Biosciences to Participate in Investor Conferences in May 2022
May 2, 2022
IDEAYA Biosciences Receives Orphan Drug Designation for Darovasertib, a PKC Inhibitor, for the Treatment of Uveal Melanoma
Apr 6, 2022
IDEAYA Biosciences Appoints Catherine Mackey, Ph.D., to its Board of Directors
Mar 15, 2022
IDEAYA Biosciences, Inc. Reports 2021 Financial Results and Provides Business Update
Mar 15, 2022
IDEAYA Biosciences Reports IDE397 Interim Phase 1 Clinical Data
Mar 14, 2022
IDEAYA and Pfizer Expand Clinical Trial Collaboration and Supply Agreements for Evaluation of Darovasertib and Crizotinib Combination in Metastatic Uveal Melanoma and Additional cMET-Driven Tumors
Mar 8, 2022
IDEAYA Biosciences Announces Investor Webcast to Report Interim IDE397 Phase 1 Clinical Data and Corporate Update
Show
5
10
25
50
100
per page
«
1
2
3
»
Company
Science
Pipeline
Newsroom
Investors
Careers
Contact
